Deletion polymorphism of glutathione S-transferases genes (GSTT1, GSTM1) in patients with breast cancer in Primorye region-Reference-Cited by-同舟云学术

Deletion polymorphism of glutathione S-transferases genes (GSTT1, GSTM1) in patients with breast cancer in Primorye region

Published:2021-01-12 Issue:3 Volume:16 Page:25-31
ISSN:1999-8627
Container-title:Tumors of female reproductive system
language:
Short-container-title:Opuholi ženskoj reproduktivnoj sistemy

Author:

Gulyan I. S.¹^ORCID,Bystritskaya E. P.²^ORCID,Chernysheva N. Yu.²^ORCID,Eliseeva E. V.³^ORCID,Apanasevich V. I.³^ORCID,Isaeva M. P.²^ORCID

Affiliation:

1. Pacific State Medical University; Far Eastern Federal University

2. G.B. Elyakov Pacific Institute of Bioorganic Chemistry

3. Pacific State Medical University

Abstract

Background. Breast cancer (BC) refers to multifactorial polygenic diseases that occur as a result of the combined interaction of genetic and environmental factors. Glutathione-mediated detoxification is of key importance in ensuring the resistance of body cells to the damaging effect of xenobiotics.Objective: to study the prevalence of deletion polymorphisms of the GSTM1 and GSTT1 genes and to establish their influence on the formation of cancer risk in patients with BC in the Primorye region (Russia).Materials and methods. The study involved 176 women with BC, aged 23 to 79 years (mean age 48 ± 13 years) and 66 conditionally healthy individuals without cancer. The detection of deletion (null) genotypes of the GSTM1 and GSTT1 was carried out using multiplex PCR followed by analysis of the melting curves of the reaction products.Results. The frequency of GSTT1-0 genotype among BC patients was higher than in the control group (14.77 % versus 6.06 %), significantly exceeding the indicators in the control group by more than 2.5 times (p <0.1), indicating an association between the carriage of the GSTT1-0 genotype and the risk of developing BC. At the same time, the frequencies of the GSTM1-0 genotype in the study groups were comparable; no statistically significant association with the risk of developing BC was found.Conclusions. Homozygous deletion of GSTT1 (GSTT1-0) can potentially be considered as a low-penetrant risk factor for developing BC in the population of Primorye region.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference24 articles.

1. Malignant tumors in Russia in 2018 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: P.A. Herzen Moscow Oncology Research Institute a branch of the National Medical Research Radiological Center, Ministry of Health of Russia, 2019. 250 p. (In Russ.).

2. Oncomammology. Ed. by V.A. Khaylenko, D.V. Komov. Moscow: MEDpress-inform, 2015. 328 p. (In Russ.).

3. Wang J., Yu L., Jiang H. et al. Epigenetic regulation of differentially expressed drugmetabolizing enzymes in cancer. Drug Metab Dispos 2020;48(9):759–68. DOI: 10.1124/dmd.120.000008.

4. Kiendrebeogo I., Zoure A., Sorgho P. et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) variants and breast cancer risk in Burkina Faso. Biomol Concepts 2019;10(1):175–83. DOI: 10.1515/bmc-2019-0020. PMID: 31707358.

5. Economopoulos K., Choussein S., Vlahos N., Sergentanis T. GSTM1 polymorphism, GSTT1 polymorphism, and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer 2010;20(9):1576–80. DOI:10.1111/IGC.0b013e3181ca1dfc.